Prochlorperazine: Difference between revisions
(common reactions) |
|||
| (13 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: anti-psychotic and anti-emetic | *Type: [[anti-psychotic]] and [[antiemetics|anti-emetic]] | ||
*Dosage Forms: 5, 10 | *Dosage Forms: 5, 10 | ||
*Routes of Administration: IV, PO | *Routes of Administration: IV, PO | ||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Headache]]=== | ===[[Headache]]=== | ||
* | *10mg IV (slow push or in 1L [[IVF]]) | ||
===[[Nausea/Vomiting]]=== | ===[[Nausea/Vomiting]]=== | ||
*5- | *5-10mg PO or IV q6-8 hours | ||
*Max: 40mg/day | *Max: 40mg/day | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
=== | ===[[Nausea and vomiting (peds)|Nausea/vomiting]], severe=== | ||
====2 yo and older, 9-14 kg==== | ====2 yo and older, 9-14 kg==== | ||
* 2. | *2.5mg PO q12-24 h; Max 7.5mg/day | ||
====2 yo and older, 14-18 kg==== | ====2 yo and older, 14-18 kg==== | ||
* 2. | *2.5mg PO q8-12 h; Max 10mg/day | ||
==== 2 yo and older, 18-39 kg==== | ====2 yo and older, 18-39 kg==== | ||
* 2. | *2.5mg PO q8 hr; Max 15mg/day | ||
==== 2 yo and older, >39 kg ==== | ====2 yo and older, >39 kg==== | ||
* | *5mg PO q6-8 h, Max: 20mg/day | ||
=== Schizophrenia=== | ===Schizophrenia=== | ||
==== 2-5 yo==== | ====2-5 yo==== | ||
* 2.5 - | *2.5 - 5mg PO q6-8 hr, Max 20mg/day | ||
====6-12 yo==== | ====6-12 yo==== | ||
*2.5- | *2.5-5mg PO q6-8 hr, Max 25mg/day | ||
==Special Populations== | ==Special Populations== | ||
| Line 64: | Line 64: | ||
===Common=== | ===Common=== | ||
*[[Akathisia]] | |||
*drowsiness | *drowsiness | ||
*dizziness | *dizziness | ||
| Line 86: | Line 87: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 3-5 hrs (oral); 7 hrs (IV) | ||
*Metabolism: | *Metabolism: liver extensively, GI tract | ||
*Excretion: | *Excretion: urine, bile/feces | ||
*Mechanism of Action: | *Mechanism of Action: selectively antagonizes dopamine D2 receptors | ||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[Antipsychotic toxicity]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 17:01, 6 October 2021
General
- Type: anti-psychotic and anti-emetic
- Dosage Forms: 5, 10
- Routes of Administration: IV, PO
- Common Trade Names: Compazine
Adult Dosing
Headache
- 10mg IV (slow push or in 1L IVF)
Nausea/Vomiting
- 5-10mg PO or IV q6-8 hours
- Max: 40mg/day
Pediatric Dosing
Nausea/vomiting, severe
2 yo and older, 9-14 kg
- 2.5mg PO q12-24 h; Max 7.5mg/day
2 yo and older, 14-18 kg
- 2.5mg PO q8-12 h; Max 10mg/day
2 yo and older, 18-39 kg
- 2.5mg PO q8 hr; Max 15mg/day
2 yo and older, >39 kg
- 5mg PO q6-8 h, Max: 20mg/day
Schizophrenia
2-5 yo
- 2.5 - 5mg PO q6-8 hr, Max 20mg/day
6-12 yo
- 2.5-5mg PO q6-8 hr, Max 25mg/day
Special Populations
- Pregnancy Rating: Pregnancy category C
- Lactation risk: Safety unknown
- Renal Dosing: not defined
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- tardive dyskinesia
- neuroleptic malignant syndrome
- blood dyscrasias
- agranulocytosis
- thrombocytopenic purpura
- orthostatic hypotension
- extrapyramidal symptoms
- cholestatic jaundice
- hepatotoxicity
- QT prolongation
- cardiac arrest
- seizures
- anaphylactoid reactions
- lupus erythematosus
- priapism
- heat stroke
- neonatal extrapyramidal symptoms (3rd trimester use)
- neonatal withdrawal symptoms (3rd trimester use)
Common
- Akathisia
- drowsiness
- dizziness
- blurred vision
- xerostomia
- constipation
- urinary retention
- headache
- nasal congestion
- nausea
- menstrual irregularities
- amenorrhea
- weight gain
- hyperprolactinemia
- hyperglycemia
- hypoglycemia
- insomnia
- agitation
- sexual dysfunction
- photosensitivity
- impaired body temperature regulation
Pharmacology
- Half-life: 3-5 hrs (oral); 7 hrs (IV)
- Metabolism: liver extensively, GI tract
- Excretion: urine, bile/feces
- Mechanism of Action: selectively antagonizes dopamine D2 receptors